STOCK TITAN

Biofrontera Inc - BFRI STOCK NEWS

Welcome to our dedicated news page for Biofrontera (Ticker: BFRI), a resource for investors and traders seeking the latest updates and insights on Biofrontera.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biofrontera's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biofrontera's position in the market.

Rhea-AI Summary
Biofrontera Inc. (NASDAQ:BFRI) will report financial results for the three and nine months ended September 30, 2023, on November 9, 2023. A conference call will be held on November 10, 2023, to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.11%
Tags
conferences earnings
-
Rhea-AI Summary
Biofrontera Inc. has entered into a securities purchase agreement with an institutional investor to issue and sell 1,205,000 shares of its common stock and warrants to purchase up to 1,807,000 shares. The exercise price for the warrants is $3.55 per share, and they will expire in five years. The company will also adjust the strike price of 385,236 outstanding warrants held by the investor to $3.55. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.68%
Tags
offering
-
Rhea-AI Summary
Biofrontera files patent application to extend Ameluz® protection until 2043
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.57%
Tags
fda approval
Rhea-AI Summary
Biofrontera to present at Roth MKM Healthcare Opportunities Conference and exhibit at Fall Clinical Dermatology Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
conferences
-
Rhea-AI Summary
Biofrontera Inc. expects revenues for Q3 2023 to increase by approximately 101% to 108% compared to Q3 2022. Revenues for the first nine months of 2023 are anticipated to grow by approximately 25% to 27% compared to the same period in 2022. The company sold approximately 29,000 tubes of Ameluz® during the quarter, compared to about 13,000 tubes in Q3 2022, with growth benefitting from buy-in ahead of a 5% price increase on October 1st. In addition, Biofrontera shipped a record 101 BF-RhodoLED® lamps during the first nine months of the year, up 180% compared to the first nine months of last year. Biofrontera affirms its expectation for full-year 2023 revenue growth of at least 25% compared to 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
none
-
Rhea-AI Summary
Biofrontera appoints Samantha Widdicombe as Senior Director, Strategic Accounts and Communications
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
management
Rhea-AI Summary
Biofrontera Inc. announces positive Phase 1 study results for BF-200 ALA in the treatment of actinic keratosis. No additional safety or tolerability issues found with 3 tubes. Intends to present findings to FDA in Q4 2023. Patient enrollment completed for Phase 3 study on Ameluz-PDT for basal cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
clinical trial
-
Rhea-AI Summary
Biofrontera Inc. reports financial results for Q2 2023, with total revenues of $5.8 million, a 31% increase from the prior-year period. Cash and cash equivalents were $4.5 million as of June 30, 2023. The company affirms guidance for 2023 revenue growth of at least 25% compared with 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
earnings
-
Rhea-AI Summary
Biofrontera Inc. completes patient enrollment in Phase 3 clinical study for Ameluz®-PDT in combination with BF-RhodoLED® lamp for basal cell carcinoma treatment. Trial results expected in mid-2024. The company aims to expand the Ameluz® label beyond actinic keratosis (AK).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
clinical trial
Rhea-AI Summary
Biofrontera Inc. (Nasdaq:BFRI) will report financial results for the three and six months ended June 30, 2023 before the opening of the U.S. financial markets on Friday, August 11, 2023. The company will hold a conference call to discuss those results, provide a business update, and answer questions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
conferences earnings
Biofrontera Inc

Nasdaq:BFRI

BFRI Rankings

BFRI Stock Data

7.84M
2.00M
31.29%
39.15%
1.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Woburn

About BFRI

biofrontera pharma gmbh is a pharmaceuticals company based out of 104 waldhofer straße, heidelberg, bw, germany.